tetano
Editor, Senior Moderator
Emerg Microbes Infect
. 2021 Mar 18;1-50.
doi: 10.1080/22221751.2021.1905488. Online ahead of print.
Cross-reactive antibody against human coronavirus OC43 spike protein correlates with disease severity in COVID-19 patients?a retrospective study
Li Guo[SUP] 1 2 [/SUP], Yeming Wang[SUP] 3 [/SUP], Liang Kang[SUP] 4 [/SUP], Yongfeng Hu[SUP] 1 [/SUP], Linghang Wang[SUP] 5 [/SUP], Jingchuan Zhong[SUP] 1 [/SUP], Hong Chen[SUP] 6 [/SUP], Lili Ren[SUP] 1 2 [/SUP], Xiaoying Gu[SUP] 7 [/SUP], Geng Wang[SUP] 1 [/SUP], Conghui Wang[SUP] 1 [/SUP], Xiaojing Dong[SUP] 1 [/SUP], Chao Wu[SUP] 1 [/SUP], Lianlian Han[SUP] 1 [/SUP], Ying Wang[SUP] 1 [/SUP], Guohui Fan[SUP] 7 [/SUP], Xiaohui Zou[SUP] 3 [/SUP], Haibo Li[SUP] 3 8 [/SUP], Jiuyang Xu[SUP] 9 [/SUP], Qi Jin[SUP] 1 [/SUP], Bin Cao[SUP] 3 8 10 [/SUP], Jianwei Wang[SUP] 1 2 [/SUP]
Affiliations
Abstract
Seasonal human coronaviruses (HCoVs) including HCoV-229E, -OC43, -NL63 and -HKU1 widely spread in global human populations. However, the relevance of humoral response against seasonal HCoVs to COVID-19 pathogenesis is elusive. In this study, we profiled the temporal changes of IgG antibody against spike proteins (S-IgG) of SARS-CoV-2 and seasonal HCoVs in 838 plasma samples collected from 344 COVID-19 patients. We tested the antigenic cross-reactivities of S protein between SARS-CoV-2 and seasonal HCoVs and evaluated the correlations between the levels of HCoV-OC43 S-IgG and the disease severity in COVID-19 patients. We found that SARS-CoV-2 S-IgG titers mounted until days 22-28, whereas HCoV-OC43 antibody titers increased until days 15-21 and then plateaued until day 46. However, IgG titers against HCoV-NL63, -229E, and -HKU1 showed no significant increase. A two-way cross-reactivity was identified between SARS-CoV-2 and HCoV-OC43. Neutralizing antibodies against SARS-CoV-2 were not detectable in healthy controls who were positive for HCoV-OC43 S-IgG. HCoV-OC43 S-IgG titers were significantly higher in patients with severe disease than those in mild patients at days 1-21 post symptom onset (PSO). Higher levels of HCoV-OC43 S-IgG were also observed in patients requiring mechanical ventilation. At days 1-10 PSO, HCoV-OC43 S-IgG titers correlated to disease severity in the age group over 60. Our data indicate that there is a correlation between cross-reactive antibody against HCoV-OC43 spike protein and disease severity in COVID-19 patients.
Keywords: HCoV-OC43; SARS-CoV-2; antibody; cross-reactivity; disease severity.
. 2021 Mar 18;1-50.
doi: 10.1080/22221751.2021.1905488. Online ahead of print.
Cross-reactive antibody against human coronavirus OC43 spike protein correlates with disease severity in COVID-19 patients?a retrospective study
Li Guo[SUP] 1 2 [/SUP], Yeming Wang[SUP] 3 [/SUP], Liang Kang[SUP] 4 [/SUP], Yongfeng Hu[SUP] 1 [/SUP], Linghang Wang[SUP] 5 [/SUP], Jingchuan Zhong[SUP] 1 [/SUP], Hong Chen[SUP] 6 [/SUP], Lili Ren[SUP] 1 2 [/SUP], Xiaoying Gu[SUP] 7 [/SUP], Geng Wang[SUP] 1 [/SUP], Conghui Wang[SUP] 1 [/SUP], Xiaojing Dong[SUP] 1 [/SUP], Chao Wu[SUP] 1 [/SUP], Lianlian Han[SUP] 1 [/SUP], Ying Wang[SUP] 1 [/SUP], Guohui Fan[SUP] 7 [/SUP], Xiaohui Zou[SUP] 3 [/SUP], Haibo Li[SUP] 3 8 [/SUP], Jiuyang Xu[SUP] 9 [/SUP], Qi Jin[SUP] 1 [/SUP], Bin Cao[SUP] 3 8 10 [/SUP], Jianwei Wang[SUP] 1 2 [/SUP]
Affiliations
- PMID: 33734013
- DOI: 10.1080/22221751.2021.1905488
Abstract
Seasonal human coronaviruses (HCoVs) including HCoV-229E, -OC43, -NL63 and -HKU1 widely spread in global human populations. However, the relevance of humoral response against seasonal HCoVs to COVID-19 pathogenesis is elusive. In this study, we profiled the temporal changes of IgG antibody against spike proteins (S-IgG) of SARS-CoV-2 and seasonal HCoVs in 838 plasma samples collected from 344 COVID-19 patients. We tested the antigenic cross-reactivities of S protein between SARS-CoV-2 and seasonal HCoVs and evaluated the correlations between the levels of HCoV-OC43 S-IgG and the disease severity in COVID-19 patients. We found that SARS-CoV-2 S-IgG titers mounted until days 22-28, whereas HCoV-OC43 antibody titers increased until days 15-21 and then plateaued until day 46. However, IgG titers against HCoV-NL63, -229E, and -HKU1 showed no significant increase. A two-way cross-reactivity was identified between SARS-CoV-2 and HCoV-OC43. Neutralizing antibodies against SARS-CoV-2 were not detectable in healthy controls who were positive for HCoV-OC43 S-IgG. HCoV-OC43 S-IgG titers were significantly higher in patients with severe disease than those in mild patients at days 1-21 post symptom onset (PSO). Higher levels of HCoV-OC43 S-IgG were also observed in patients requiring mechanical ventilation. At days 1-10 PSO, HCoV-OC43 S-IgG titers correlated to disease severity in the age group over 60. Our data indicate that there is a correlation between cross-reactive antibody against HCoV-OC43 spike protein and disease severity in COVID-19 patients.
Keywords: HCoV-OC43; SARS-CoV-2; antibody; cross-reactivity; disease severity.